Preferred Label : bezlotoxumab;
UNII : 4H5YMK1H2E;
Origin ID : C000613978;
UMLS CUI : C4291320;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://smf.swisshealthweb.ch/fr/article/doi/fms.2018.08011/
2018
false
false
false
Switzerland
journal article
blood group antibody di a
blood group antibody lu a
blood group antibody bx a
blood group antibody le bh
blood group antibody cr3
blood group antibody yk a
blood group antibody pt a
blood group antibody pr a
blood group antibody le x
blood group antibody at a
blood group antibody au a
blood group antibody tg a
blood group antibody lw b
blood group antibody a x
blood group antibody mcc a
blood group antibody sk a
blood group antibody a1
blood group antibody en afs
blood group antibody rh a
blood group antibody rd a
blood group antibody nijhuis
blood group antibody an a
blood group antibody xg a
blood group antibody s1a
blood group antibody rb a
blood group antibody be a
blood group antibody th a
blood group antibody mt a
blood group antibody kn a
blood group antibody wr a
blood group antibody li a
blood group antibody je a
blood group antibody sw a
blood group antibody le bl
blood group antibody wk a
blood group antibody dh a
blood group antibody m a
blood group antibody jn a
blood group antibody fy a
blood group antibody hg a
blood group antibody es a
blood group antibody lan
blood group antibody m'
blood group antibody pr a
blood group antibody gy a
blood group antibody jc a
infectious disease, nos
blood group antibody cs a
blood group antibody a.m.
blood group antibody r1a
Infections
blood group antibody go a
blood group antibody ht a
blood group antibody cl a
blood group antibody m1a
blood group antibody en akt
blood group antibody 'n'
blood group antibody a2
blood group antibody c
blood group antibody dr a
Infectious disease
blood group antibody le a
blood group antibody ol a
blood group antibody vr
bezlotoxumab
blood group antibody le c
blood group antibody fr a
blood group antibody sd a
blood group antibody os a
blood group antibody re a
blood group antibody yt a
blood group antibody en afr
blood group antibody zt a
blood group antibody do a
blood group antibody en ats
blood group antibody or a
blood group antibody le d
blood group antibody chr a
antibodies
blood group antibody lw a
blood group antibody le ns
blood group antibody kp a
blood group antibody tj a
blood group antibody a3
blood group antibody ls a
blood group antibody bg a
blood group antibody wd a
blood group antibody sc2
blood group antibody tr a
blood group antibody co a
blood group antibody n a
blood group antibody js a
blood group antibody mo a
blood group antibody u1a
blood group antibody jo a
therapeutics
blood group antibody rh42
blood group antibody ri a
blood group antibody ch a
blood group antibody jk a
blood group antibody a1 le d
antibody, nos
blood group antibody a1 le b
blood group antibody sf a
blood group antibody vg a
blood group antibody le b
blood group antibody yh a
blood group antibody bp a
blood group antibody a.m.
blood group antibody er a
blood group antibody c
blood group antibody ok a
blood group antibody le s
blood group antibody mi a
blood group antibody rg a
blood group antibody st a
blood group antibody jr a
blood group antibody in a
blood group antibody ny a
blood group antibody to a
antibodies, monoclonal
antibodies, neutralizing
---
https://www.ema.europa.eu/medicines/human/EPAR/Zinplava
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
antibodies, monoclonal
antibodies, monoclonal
treatment outcome
antibodies, neutralizing
antibodies, neutralizing
adult
bezlotoxumab
enterocolitis, pseudomembranous
enterocolitis, pseudomembranous
diarrhea
toxB protein, clostridium difficile
infusions, intravenous
product surveillance, postmarketing
recurrence
aged
drug interactions
pregnancy
breast feeding
bezlotoxumab
bezlotoxumab
bacterial proteins
bacterial toxins
---
https://www.has-sante.fr/portail/jcms/c_2792203/fr/zinplava
2017
false
false
false
France
French
antibodies, monoclonal
treatment outcome
antibodies, neutralizing
adult
bezlotoxumab
toxB protein, clostridium difficile
infusions, intravenous
recurrence
aged
immunocompromised host
evaluation of the transparency committee
Clostridium difficile infection
drug therapy, combination
anti-bacterial agents
clostridium infections
Clostridioides difficile
clostridium infections
vancomycin
metronidazole
At increased risk for relapse (finding)
risk
clostridium infections
diarrhea
Clostridium difficile diarrhea (disorder)
bezlotoxumab
bacterial proteins
bacterial toxins
---